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Since its imroduclion by Gmentrig (I). coronary angioplasty 
has evolved into an increasingly sophisticated technical 
procedure. Although initially used for single discrete ob- 
structions, tt is now being offered to patients with multilesion 
and multivessel coronary artery disease, distal coronary 
disease. poor left vent&dar function, previous coronary 
artery bypars grafts and acute myocardial infarction (Ml. 
Despite these added risks, the emergency surgery rate 
associated with an%ioplasty has declined and the nngioplasty 
SUCEW rate has improved since 1982 (5). However, the 
paucity of long-term follow-up data in complicated cases has 
dampened cnlhuriasm for the widespread extension of 
angioplasty 10 patients other than those with single vessel 
coronary diserw rcsisIanf to medical managcmenl (6.7). 
Optimal care of patients with coronary artery disexe 
requires the cooperative efforts of interventional and oonin- 
tewentional cardiologists and cardiac surgeons. Further data 
must be collected and analyzed to determine the proper 
utilization of coronary angioplasty BE a therapeutic altema- 
tive. The article of Deligonul et al. (8) in this issue of the 
Journal provides important information on the angiographic 
SUCCESS rate, complication rate and intermediate Penn fo!- 
low-up of patients with two and three vessel coronary 
disease trealed with angioplasly. 
Initial an@graphic results. The initial angiogmphic SUE- 
cess rate for multilesion percutaneous transluminal coronary 
angioplasty has exceeded 9&b in several recent reports 
(2.3.~12). However. the number of patients with multives- 
sel angiopia5ty versus multilesion angioplasty in a single 
vessel eannol ix determined in many of these studies. 
Delisonul et ai. (8) hdve provided important data by identi. 
fying the exlenl of coronary artery disease in their patients. 
The initial angiograpbic success rate of86% in Patients with 
multivessel disease is lower than the success rate of 94% 
reported by this same group (IO) in multitesion angioplasty. 
To determine whether a lower initial angiogrdphic success 
rate can be expected with multiveaset angioplasty than with 
multilesion angioplasty in single vessel disease will require 
funher study. 
Complkatkms. For angioplasty to become established as 
an alcernadve to coronary artery bypass surgery in patients 
with multilesion. multivessel disease. mortality rates will 
have to be substantially improved over the 2.3%.mported by 
Deligonul Ed at. (8) and the 2.8% in patients with triple vessel 
d&se reponed from the 1985-1986 angioplasty registry (5). 
The explanation of tkligonul et al. thai four of the nine 
patients who died were “nonoperative candidates” may 
gccount in part for the mortality&e. However, the cd& 
for “nonoperative” candidacy were not defined and the 
number of nonoperative patients was not tabulated. The 
mortality rate was still t .% when nonoperative candidate 
deaths were excluded (8). The mortality rate for primary 
elective coronary artery bypass surgery in patients &th two 
and three vessel disease was 1.6% at the Cleveland Clinic in 
1986 (unpublished data). Unless multivessel angioplasty is 
associated wilh a significantly lower mortality rate than that 
of bypass soracy in operative candidates, its role wilt he 
limited. However, otheigroups (2-l I) report a mortality rate 
approaching 1% in patients undergting multilesion angio- 
plasty. Two direct cornprisons of patients with muttivesBel 
disease randomized to coronary angioplasty versus bypass 
surgery are planned, and the results will be important in 
assessing the relative morbidity and mortality rates. 
Emergency bypass mrgrry WJ required in 6.4% of the 
pntienrs rpponed on by Drligonal EI nl. IS). Data from the 
coronary angioplasty registry (5) indicate that 3.7 and 4.3%. 
respe-tivety. of patients with two and three vessel disease 
treJtsd with angioplaaty required emergency surgery. Other 
groups have reported a lower emergency surgery rate for 
patients with multilesion dilation, but the extent of coronaw 
artery disease in these patients is not clear. Emergency 
bypass surgery usually requires use cf rdphenous veins 
rather thsn mammary arteries as conduits. and myocardiat 
infarction evolves in approximately 50% lt3). The overall 
myocardial infarction rate of Deligonul et al. (8) was 2.1% 
and that of the 1985-1986 registry (5) was 4.3%. The risks of 
emergency surgery. myoc&diai infar&” and death will 
have to be carefully considered when recommending angio- 
plasty 10 patients with multilesion. multivessel c&ondry 
disease. 
Angiographiifollow-up. Sixty percent of eligible patients 
reponcd on by Deligonul et al. (81 returned for angiOgraQhy 
I year fter angioplasly. and the restenosis rate per lesion in 
this group was 28%. This rate is similar to the 23% reported l&tic regression to adjost for baseline differences in left 
by Mata, et al. (I I) 6 months efter angioplasty in patients 
with two lesion dilation and 96% complete angiogmphtc 
ventricular function. Comparing I27 patients with complete 
follow-up. Restenosis appean to be related more to the 
~ersos I59 patients with incomplete revascularizalion. there 
“as no difference between the stews of the two cohorts at 2 
lesion than to the patient because an increased incidence of year follow-up. Likewise. Thomas et al. (21) found no 
restenosis per patient occurs when mul!iale lesions and difference in clinical imorovement after mottivew3 an&. 
multi& vessels are amroached. Fiftr oe& of the oa- , .- 
tie& of Deligonul et ai. (8) with angioplasty in more than 
one lesion or vessel and 34% of the patients with two vessel 
dilation reported on by M&a et al. (I I) had restenosis. 
However, Myler et al. (4) found that several patient-related 
variables are also predictive of restenosis in multilesron 
angioplasty. Patients with diabetes mellitus, hypercholester- 
olemia, continued smoking and recent onset $g:,la had an 
increased risk of restenosis. 
The high rote of resrrnosis is tt de/errcnt to extenlng 
angioplarry IO patients with mrdrilesion disease. Before 
undergoing multilesion multivessel angioplasty, patients 
should aecept angioplasty a5 an initial treatment strategy 
rather than as a definitive procedure because many of them 
Will require multiple procedures. Patients accepting this 
strategy will require close follow-up with frequent functional 
testing or repeat angiography. The high rate of restenosts 
may defer widespread acceptace of multilesion angioplasty 
for patients with multivessel disease until methods for rc- 
duciog restenosis are developed (14). 
Complete verses inecenpkte rew3eolarization. Deligonol 
et al. (8) report that 7% of patients are alive and have not 
had myocardial infarction or a need for bypass surgery at an 
average follow-up interval of 2 years. Of the event-free 
group. 8W were free of angina or had Canadian C!ISS f 
symptoms. The functional I!Z!BE of :hese &rns treated 
with multivessel. multilesion angiaplasty appears excellem, 
especially considering that 250% of the treatment group 
received “incomplete revascularization: 
Surgical repoRs(l5.16)docoment an improved event-free 
survival rate with complete verw incomplete revasculimzz- 
tion. However. incomplete revascularizatian with angio- 
plasly may be quite di&rent from that associated with 
bypass surgery. If coronary artery disease progresses from 
subcritical nerrowine to sienificant stenosis after initial 
angioplasty. the pat&nt &undergo a repad procedure. 
Repeat anriovlasty will likely be associated with less mor- 
bidity, #no&&y and cost than will repeat bypass surgery. 
Nonetheless, patients must udergo another angioplasty. 
which is not free of risk or cost. 
Angioplasty of /be “rrdprit ksion” o&rs an attractive 
alternative to the treatment of patients with multivessel 
coronary artery disease who have unsuccessful medical 
therapy.(l7). however. severe1 studies (8.18.19). including 
that of Deligonul et al. (8). report a less fworable long_term 
outlook for patients with angioplasty and incomplete revas- 
cularization. The 1985-1986 registry patients i20) with wc- 
cessful dilation tar multivessel disease were analyzed with 
plasty between patients who received incomplete rather rban 
complete revaw&rization. More information is needed to 
clarify the role of complete revascularizarica in the long- 
term outcome of multivessel, multilesion angioplasty. 
Conclusions. Coronary angioplasty can be utilized with a 
high degree of angiographic and clinical success in selected 
symptomatic patient, with multivessel coronary anery dis- 
case. Angioplasty equipment and experience have evolved 
such that in 1988 more extensive and complex coronary 
artery disease can be managed by coronary angioplasty with 
a risk of emergency surgery and myocardial infarction 
similar to that ofsingle vessel angioplasty in the early 1980s. 
The mortality rate associated with multivesscl angioplasty 
may approach that found with coronary artery bypass WI- 
gay. Anpioplasty offers an alternative for selected patients 
who are at high surgical risk, have had previous bypass 
surgery or have extensive distal disease and are not suitable 
candidates for bypass surgery. Multivessel angioplasty mey 
also be used in selected patients to permit delay of bypass 
surgery oniil coronary artery disease becomes extensive 17). 
The majority of patients with multivessel coronary disease 
are candidates for bypass sorwy. A controlled clinical trial 
of multivessel. multilesion &ioplasty verses bypass sor- 
gery is needed to determine the merits of these alternatives 
for our patients. Unless the ratec of restenosis and proce- 
dure-related mortality decline. coronary angioplasty will 
remain complementary to but not competitive with bypass 
sorgery for moat patients with two or three vessel coronary 
artery disease. 
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